SEC Form 3 · accession 0001654954-18-000210
Monopar Therapeutics · MNPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Michael J Brown
Director · 10% Owner
Chandler Robinson
Officer — Chief Executive Officer · Director · 10% Owner
Tactic Pharma LLC
10% Owner
Andrew Paul Mazar
Officer — Chief Scientific Officer · Director · 10% Owner
Thomas V. O'Halloran
10% Owner
Period of report
Jan 8, 2018
Accepted (ET)
Jan 8, 2018 · 6:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645469
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1,F2 | holding | — | — | — | 4,111,273 | I | See Footnotes (1) and (2) | |
| Common stockF1 | holding | — | — | — | 166,667 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This Form 3 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein.
- F2Tactic shares voting and investment power over 4,111,272.88 of the shares of common stock held by TacticGem LLC.